CA2702903C - Process for the modification of the solid state of a compound and co-amorphous compositions produced with same - Google Patents

Process for the modification of the solid state of a compound and co-amorphous compositions produced with same Download PDF

Info

Publication number
CA2702903C
CA2702903C CA2702903A CA2702903A CA2702903C CA 2702903 C CA2702903 C CA 2702903C CA 2702903 A CA2702903 A CA 2702903A CA 2702903 A CA2702903 A CA 2702903A CA 2702903 C CA2702903 C CA 2702903C
Authority
CA
Canada
Prior art keywords
crystalline
ezetimibe
aspirin
laser
simvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2702903A
Other languages
English (en)
French (fr)
Other versions
CA2702903A1 (en
Inventor
Todd F. Ovokaitys
John Scott Strachan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2702903A1 publication Critical patent/CA2702903A1/en
Application granted granted Critical
Publication of CA2702903C publication Critical patent/CA2702903C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
CA2702903A 2007-10-17 2008-10-16 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same Expired - Fee Related CA2702903C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US99946207P 2007-10-17 2007-10-17
US99948307P 2007-10-17 2007-10-17
US99944507P 2007-10-17 2007-10-17
US60/999,445 2007-10-17
US60/999,462 2007-10-17
US60/999,483 2007-10-17
US12/252,458 2008-10-16
PCT/US2008/080095 WO2009052246A1 (en) 2007-10-17 2008-10-16 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
US12/252,458 US8173632B2 (en) 2007-10-17 2008-10-16 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same

Publications (2)

Publication Number Publication Date
CA2702903A1 CA2702903A1 (en) 2009-04-23
CA2702903C true CA2702903C (en) 2016-01-19

Family

ID=40567777

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2702903A Expired - Fee Related CA2702903C (en) 2007-10-17 2008-10-16 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same

Country Status (10)

Country Link
US (1) US8173632B2 (de)
EP (1) EP2211611B1 (de)
JP (1) JP5596547B2 (de)
CN (1) CN101969766B (de)
BR (1) BRPI0818575A2 (de)
CA (1) CA2702903C (de)
EA (1) EA023338B1 (de)
IL (1) IL205155A (de)
WO (1) WO2009052246A1 (de)
ZA (1) ZA201003353B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702909C (en) * 2007-10-17 2016-05-10 Todd F. Ovokaitys Room temperature stable non-crystalline aspirin
WO2010113175A2 (en) 2009-04-01 2010-10-07 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
EP2368543A1 (de) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung einer granulierten pharmazeutischen Zusammensetzung mit Simvastatin und/oder Ezetimibe
CN103360357B (zh) * 2013-08-07 2015-07-22 中国药科大学 辛伐他丁格列齐特共无定型物
CN104415042A (zh) * 2013-08-30 2015-03-18 天津药物研究院 一种共无定型系统及其制备方法
CN103923049A (zh) * 2014-05-05 2014-07-16 武汉远瞩医药科技有限公司 黄芩素咖啡因共无定型物
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
US11453840B2 (en) * 2018-04-28 2022-09-27 John Anton Broadhurst Method for applying energy to cannabidiol
WO2020262455A1 (ja) * 2019-06-25 2020-12-30 味の素株式会社 共非晶質構造を有するアミノ酸混合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525103D0 (en) 1995-12-08 1996-02-07 Strachan John S Optical device and method of manufacture
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
IT1312115B1 (it) * 1999-06-24 2002-04-04 Nicox Sa Composti amorfi e relative composizioni farmaceutiche
GB9920351D0 (en) * 1999-08-28 1999-11-03 Strachen John S Sparse constructive node stimulation of cell surface molecular resonance in vivo
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
CZ292832B6 (cs) * 2001-08-30 2003-12-17 Ivax Pharmaceuticals S.R.O. Způsob přípravy silymarinu se zvýšenou rozpustností
EP1444041A2 (de) 2001-09-21 2004-08-11 Solvias AG Dichtungssystem mit fluidkanälen
RU2278659C9 (ru) * 2002-02-01 2007-02-20 Пфайзер Продактс Инк. Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
US20040230257A1 (en) 2003-02-10 2004-11-18 Ovokaitys Todd F. Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
EP1898911A1 (de) * 2005-06-13 2008-03-19 Elan Pharma International Limited Nanopartikelkombinationsformulierungen aus clopidogrel und aspirin
WO2007100614A2 (en) * 2006-02-24 2007-09-07 Scidose, Llc STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR

Also Published As

Publication number Publication date
EP2211611B1 (de) 2014-12-10
EA201070467A1 (ru) 2011-06-30
EP2211611A4 (de) 2012-03-28
EA023338B1 (ru) 2016-05-31
IL205155A (en) 2017-12-31
ZA201003353B (en) 2011-12-28
CA2702903A1 (en) 2009-04-23
WO2009052246A1 (en) 2009-04-23
BRPI0818575A2 (pt) 2014-10-07
IL205155A0 (en) 2010-11-30
CN101969766B (zh) 2015-05-06
CN101969766A (zh) 2011-02-09
JP2011500709A (ja) 2011-01-06
US8173632B2 (en) 2012-05-08
JP5596547B2 (ja) 2014-09-24
US20090131376A1 (en) 2009-05-21
EP2211611A1 (de) 2010-08-04

Similar Documents

Publication Publication Date Title
CA2702903C (en) Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
Singh et al. Rutin-phospholipid complex: an innovative technique in novel drug delivery system-NDDS
Nielsen et al. Spatial confinement can lead to increased stability of amorphous indomethacin
KR100773658B1 (ko) Ｏ-아세틸살리실산의 염기성 아미노산과의 안정한 염
CA2702909C (en) Room temperature stable non-crystalline aspirin
Lin Mechanochemical approaches to pharmaceutical cocrystal formation and stability analysis
Kakran et al. Ternary dispersions to enhance solubility of poorly water soluble antioxidants
Mellah et al. New Cocrystallization Method: Non-photochemical Laser-Induced Nucleation of a Cocrystal of Caffeine–Gallic Acid in Water
Tizaoui et al. The persistence and crystallization behavior of atorvastatin calcium amorphous dispersions in polyvinylpyrrolidone
Utami et al. Formation and characterization of mefenamic acid-nicotinamide cocrystal during co-milling based on X-ray powder diffraction analysis
TWI481407B (zh) 改質化合物之固體狀態的方法及以此製得之共－非晶形組合物
El-Nabarawi et al. Optimization of class II BCS drug using solid dispersion technique
Shinde et al. Enhancement solubility and dissolution rate of Paracetamol and Ibuprofen by co-amorphous particles using microwave technique
Solanki Development of parenteral formulation of poorly water soluble drugs: the role of novel mixed-solvency concept
Shazly Effect of sulindac binary system on in vitro and in vivo release profiles: an assessment of polymer type and its ratio
Kapoor et al. Amorphization of Low Soluble Drug with Amino Acids to Improve Its Therapeutic Efficacy: a State-of-Art-Review
Rashid et al. Eutectic Mixtures: A Promising Solvent in Drug Delivery System
Padalkar et al. Formulation and characterization of novel solid dispersions of hydrochlorothiazide by solvent evaporation technique
JP2009508932A (ja) 非晶質アトルバスタチンのアニーリングプロセス
Kathiriya PREPARATION AND CHARACTERIZATION OF SOLID DISPERSION OF MODAFINIL USING PEG6000 AS HYDROPHILIC CARRIER FOR IMPROVEMENT OF DISSOLUTION PROFILE
HASANAH et al. TENOXICAM-TROMETHAMINE MULTICOMPONENT CRYSTAL: PHYSICOCHEMICAL CHARACTERISTICS, SOLUBILITY, AND DISSOLUTION EVALUATION
Clout Studying Phase Transitions and Co-crystallisation in Pharmaceutical Materials
Li Stability assessment of solid dispersion systems
Vasantrao Study of Solubility Enhancement of Anagrelide HCL by Solid Dispersion
Fussell Coherent anti-Stokes Raman scattering microscopy for pharmaceutics: a shift in the right direction

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130724

MKLA Lapsed

Effective date: 20181016